The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cymeval     [2-[(2-amino-6-oxo-3H-purin- 9-yl)methoxy]...

Synonyms: Valganciclovir, SureCN28996, SureCN28998, CHEMBL1201314, CHEBI:63635, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Valcyt

  • Cytomegalovirus-induced hemorrhagic cystitis in AIDS patient treated successfully with valganciclovir [1].
  • Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy [2].
  • Therefore, when used as prophylaxis against CMV infection and disease in high-risk solid organ transplant recipients or as induction and maintenance therapy of CMV retinitis in patients with AIDS, oral valganciclovir is an attractive alternative to other available anti-CMV drugs [3].
  • EBV infection was common, although incidence of high-level EBV DNAemia was low, especially in patients who received valganciclovir prophylaxis [4].
  • Viremia was suppressed during prophylaxis when exposure to ganciclovir was 40-50 microg.h/ml, AUCs typical of those achieved in valganciclovir-treated patients [5].

Psychiatry related information on Valcyt


High impact information on Valcyt


Chemical compound and disease context of Valcyt


Biological context of Valcyt


Anatomical context of Valcyt


Associations of Valcyt with other chemical compounds


Gene context of Valcyt


Analytical, diagnostic and therapeutic context of Valcyt


  1. Cytomegalovirus-induced hemorrhagic cystitis in AIDS patient treated successfully with valganciclovir. Studemeister, A. AIDS (2002) [Pubmed]
  2. Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy. González, H., Vernant, J.P., Caumes, E. Leukemia (2005) [Pubmed]
  3. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Cvetković, R.S., Wellington, K. Drugs (2005) [Pubmed]
  4. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. Razonable, R.R., Brown, R.A., Humar, A., Covington, E., Alecock, E., Paya, C.V. J. Infect. Dis. (2005) [Pubmed]
  5. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Wiltshire, H., Paya, C.V., Pescovitz, M.D., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., Zuideveld, K.P. Transplantation (2005) [Pubmed]
  6. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Kalpoe, J.S., Schippers, E.F., Eling, Y., Sijpkens, Y.W., de Fijter, J.W., Kroes, A.C. Antivir. Ther. (Lond.) (2005) [Pubmed]
  7. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. Kim, I., Chu, X.Y., Kim, S., Provoda, C.J., Lee, K.D., Amidon, G.L. J. Biol. Chem. (2003) [Pubmed]
  8. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Czock, D., Scholle, C., Rasche, F.M., Schaarschmidt, D., Keller, F. Clin. Pharmacol. Ther. (2002) [Pubmed]
  9. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. Martin, M., Gilbert, C., Covington, E., Boivin, G. J. Infect. Dis. (2006) [Pubmed]
  10. Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Peyrière, H., Jeziorsky, E., Jalabert, A., Cociglio, M., Benketira, A., Blayac, J.P., Hansel, S., Margueritte, G., Hillaire-Buys, D. The Annals of pharmacotherapy. (2006) [Pubmed]
  11. Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy. Stevens, S.J., Zwaan, C.M., Verkuijlen, S.A., Middeldorp, J.M. Head Neck (2006) [Pubmed]
  12. Treatment of acute retinal necrosis syndrome. Aizman, A. Drugs of today (Barcelona, Spain : 1998) (2006) [Pubmed]
  13. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Asberg, A., Humar, A., Rollag, H., Jardine, A.G., Mouas, H., Pescovitz, M.D., Sgarabotto, D., Tuncer, M., Noronha, I.L., Hartmann, A. Am. J. Transplant. (2007) [Pubmed]
  14. Valganciclovir. Curran, M., Noble, S. Drugs (2001) [Pubmed]
  15. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. Mattes, F.M., Hainsworth, E.G., Hassan-Walker, A.F., Burroughs, A.K., Sweny, P., Griffiths, P.D., Emery, V.C. J. Infect. Dis. (2005) [Pubmed]
  16. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. Marfori, J.E., Exner, M.M., Marousek, G.I., Chou, S., Drew, W.L. J. Clin. Virol. (2007) [Pubmed]
  17. Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Kosobucki, B.R., Goldberg, D.E., Bessho, K., Koh, H.J., Rodanant, N., Labree, L., Cheng, L., Schrier, R.D., Azen, S.P., Freeman, W.R. Am. J. Ophthalmol. (2004) [Pubmed]
  18. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Winston, D.J., Baden, L.R., Gabriel, D.A., Emmanouilides, C., Shaw, L.M., Lange, W.R., Ratanatharathorn, V. Biol. Blood Marrow Transplant. (2006) [Pubmed]
  19. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. Boivin, G., Gilbert, C., Gaudreau, A., Greenfield, I., Sudlow, R., Roberts, N.A. J. Infect. Dis. (2001) [Pubmed]
  20. Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation. Fortún Abete, J., Martín-Dávila, P., Moreno, S., Quijano, Y., de Vicente, E., Pou, L. Antimicrob. Agents Chemother. (2004) [Pubmed]
  21. Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Umapathy, N.S., Ganapathy, V., Ganapathy, M.E. Pharm. Res. (2004) [Pubmed]
  22. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. Kogelnik, A.M., Loomis, K., Hoegh-Petersen, M., Rosso, F., Hischier, C., Montoya, J.G. J. Clin. Virol. (2006) [Pubmed]
  23. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Ayala, E., Greene, J., Sandin, R., Perkins, J., Field, T., Tate, C., Fields, K.K., Goldstein, S. Bone Marrow Transplant. (2006) [Pubmed]
  24. Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Rerolle, J.P., Szelag, J.C., Le Meur, Y. Nephrol. Dial. Transplant. (2007) [Pubmed]
  25. Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. Li, F., Hong, L., Mau, C.I., Chan, R., Hendricks, T., Dvorak, C., Yee, C., Harris, J., Alfredson, T. Journal of pharmaceutical sciences. (2006) [Pubmed]
  26. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. Kimberlin, D.W., Acosta, E.P., Sánchez, P.J., Sood, S., Agrawal, V., Homans, J., Jacobs, R.F., Lang, D., Romero, J.R., Griffin, J., Cloud, G.A., Lakeman, F.D., Whitley, R.J. J. Infect. Dis. (2008) [Pubmed]
  27. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. Sugawara, M., Huang, W., Fei, Y.J., Leibach, F.H., Ganapathy, V., Ganapathy, M.E. Journal of pharmaceutical sciences. (2000) [Pubmed]
  28. Focus on new drugs in development against human cytomegalovirus. Emery, V.C., Hassan-Walker, A.F. Drugs (2002) [Pubmed]
  29. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. Lalezari, J., Lindley, J., Walmsley, S., Kuppermann, B., Fisher, M., Friedberg, D., Lalonde, R., Matheron, S., Nieto, L., Torriani, F.J., Van Syoc, R., Sutton, M.A., Buhles, W., Stempien, M.J. J. Acquir. Immune Defic. Syndr. (2002) [Pubmed]
  30. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. Boivin, G., Goyette, N., Gilbert, C., Covington, E. J. Med. Virol. (2005) [Pubmed]
  31. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Singh, N., Wannstedt, C., Keyes, L., Gayowski, T., Wagener, M.M., Cacciarelli, T.V. Transplantation (2005) [Pubmed]
  32. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Wiltshire, H., Hirankarn, S., Farrell, C., Paya, C., Pescovitz, M.D., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N. Clinical pharmacokinetics. (2005) [Pubmed]
  33. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. Boivin, G., Goyette, N., Gilbert, C., Roberts, N., Macey, K., Paya, C., Pescovitz, M.D., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., Covington, E. J. Infect. Dis. (2004) [Pubmed]
WikiGenes - Universities